Restucturing Proteomics: The rise of next-generation affinity reagents By Dr Paul Ko Ferrigno & Dr Jane McLeod The ability of antibodies to bind their target proteins with some degree of specificity has elevated them to being among the most useful tools in biology and medicine, with a market value of… Read More
Cell Death: Discriminating between apoptosis, necrosis & autophagy By Dr John Abrams, Dr William G. Telford & Louise Rollins Cell death is crucial for the proper execution of normal and pathophysiological processes and is ubiquitous in biological systems. Programmed forms of cell death are responsible for producing morphological patterns during… Read More
Immunoassay Automation: Hands-free platforms set to change the workflow in research labs By Dr John Comley The automation of immunoassays is not a new trend, but one that has already witnessed decades of innovation in diagnostic laboratories. However, in terms of hands-free automated processing of small batches of immunoassays in… Read More
Therapeutic Drug Repurposing, Repositioning and Rescue Part I: Overview By Dr Stephen Naylor & Judge M. Schonfeld The pharmaceutical industry is still beleaguered by escalating costs, stagnant productivity and protracted timelines as it struggles to bring therapeutic drugs to market. This situation has been compounded by a ravenous generic drug… Read More
Opportunities For Phenotypic Screening In Drug Discovery By David C. Swinney Renewed awareness of the value of phenotypic screening to drug discovery creates many new opportunities to increase drug discovery success and productivity. These opportunities include identification of translational phenotypic biomarkers, development of new assays that translate to human disease… Read More
Automated Patch Clamping Finally Achieves High Throughput By Dr John Comley Two new third-generation automated patch clamp (APC) systems capable of high throughput processing (10,000 data points per eight-hour day) and full robotic integration have been recently launched. The resulting wider choice of primarily 384 APC systems has the potential… Read More
Industrial-Scale Screening Accelerates Discovery of Novel Drug Combination Therapies By Dr Oliver Leven and Dr Eric Tang Drug combination therapies are widely recognised as essential therapeutic treatments for chronic conditions ranging from infectious diseases to cancer and HIV/AIDS. Such therapies can enhance a clinical efficacy profile, improve the therapeutic window… Read More
Principles for Winning Digital Health Strategies By Dr Thilo Kaltenbach In a recent study on digital health in the pharmaceutical industry, management consultancy Arthur D. Little provided an industry snapshot of pharmaceutical companies’ goals for 2020 and their progress so far. The study indicated that by 2020, the business model… Read More
There is no excerpt because this is a protected post. To read this content in full, you need to login. Not yet a DDW member? Join now for FREE – it takes less than 2 minutes! Username or E-mail Password Remember Me … Read More
Reconfiguring Drug Discovery Through Innovative Partnerships By Dr Robert Grundy, Iain James, Chas Bountra and Timothy Harrison Attrition rates in drug discovery and development remain stubbornly high, despite large investments by the pharmaceutical industry. The cost of developing a new drug has been estimated at between $1.3 billion and upwards… Read More
By Dr Scott R. Burger, Louis Juliano, and Dr Wenshi Wang For more than two decades, the biotechnology and pharmaceutical industries have been working to unlock the great potential of cell therapy, which uses products composed of living, functional cells to mediate the therapeutic effect. These novel biologics have potential… Read More
Targeted Chemical Libraries: The keys to unlock the ubiquitin system By Dr Jason Brown and Dr J. Mark Treherne Is novel chemistry the final frontier for ubiquitin system drug discovery? Although the widespread use of target-focused libraries has led to the rapid expansion of novel chemistry as research… Read More
Oncology Target Discovery by RNAi: The past, present, and future perspectives By Dr Hakim Djaballah and Bhavneet Bhinder Despite an investment of billions of US dollars in the search of novel therapies, cancer still remains the leading cause of death in the world. This emphasises the need to identify novel… Read More
New Tools Bring Greater Understanding to Cellular Metabolism Research By Dr John Comley The links between mitochondrial dysfunction and various diseases and pathological conditions are being increasingly revealed, such that mitochondrial analyses have gained renewed interest from both the academic research and drug discovery labs. This revival of interest in… Read More
Automating The Drive Towards Personalised Medicine By Dr Alexandre Akoulitchev, Dr Howard Womersley and Dr Phil Jordan Interest in personalised medicine continues to grow, and epigenetic biomarkers are very informative in this respect, giving a clear indication of whether (and how) a patient’s gene expression profile has changed, as well… Read More
Could The Keys To Precision & Personalised Medicine Be Rooted In Predictive Safety & Research Methods? By Robert G. Hunter To meet the massive challenges of future healthcare, perhaps no two facets hold greater promise than biomarkers for precision medicine and systems biology for personalised patient care. Although a high… Read More